KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
Pembrolizumab combined with chemoradiotherapy and then continued post-chemoradiotherapy demonstrates significant improvements in progression-free survival compared to chemoradiotherapy alone